ITW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ITW is not a good buy right now for a Beginner long-term investor with fresh capital who wants a clear, immediate entry. The stock is sitting near support in pre-market, but the technical trend is still weak, analyst sentiment is mixed-to-negative, insiders and hedge funds are selling, and there is no recent news catalyst to push momentum higher. I would not buy aggressively at this moment; the better call is to hold and wait for a cleaner trend reversal or stronger fundamental confirmation.
Current price is 250.04 in pre-market, essentially flat. The technical setup is bearish to neutral: MACD histogram is negative and still contracting, RSI_6 is 42.55 (neutral but below 50), and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. That points to a downtrend rather than a confirmed rebound. Key levels: pivot 250.698, resistance at 255.63, support at 245.766. The stock is trading just below the pivot, so near-term direction is still undecided, but the trend bias remains weak.
Congress trading is positive: 2 recent congressional purchases and 0 sales, with trade sizes ranging from $0.2M to $3.0M and a median of $1.6M, which is a constructive signal. The options market also shows a lower put-call ratio, suggesting some bullish positioning. The stock is also near a technical pivot/support zone, which could attract dip buyers if it stabilizes.
No news in the recent week means no fresh catalyst. Hedge funds are selling heavily, insiders are also selling sharply, and analyst revisions have leaned cautious with multiple Underweight/Sell ratings and lower price targets from key firms. The pattern-based trend data also points to downside probabilities over the next week and month. The bearish moving-average structure adds to the weak setup.
Latest quarter financials were not provided due to an error in the financial snapshot, so there is no reliable quarter-by-quarter growth read here. Because the latest quarter season is unavailable, I cannot confirm whether revenue, EPS, or margins are improving from the most recent report.
Analyst sentiment is mixed but skewed negative. Recent actions include Evercore lowering its target to $272 and keeping Underperform, Wells Fargo raising target to $255 but keeping Underweight, Citi raising to $287 and keeping Neutral, JPMorgan lowering target to $295 while keeping Overweight, Goldman maintaining Sell with a target of $254, and Barclays/Wells also leaning Underweight. Wall Street’s pros view is that margin expansion and some end-market recovery could help, while the cons view is that demand is still questioned, short-cycle capex remains uneven, and margin pressure has been evident in parts of the business. Overall, pros are weaker than cons right now.
